Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Christoph Schifflers, Philipp M. Roessner, Marit Krötschel, Fabian Kilpert, Stephan Stilgenbauer, Leopold Sellner, Ekaterina Lupar, Ana Izcue, Sascha Dietrich, Marie Bordas, Ann-Christin Gaupel, Lavinia Arseni, Sebastian J. Arnold, Tobias Roider, Martina Seiffert, Laura Llaó Cid, Dolors Colomer, Peter Lichter
Publikováno v:
Leukemia
Roessner, P M, Llaó Cid, L, Lupar, E, Roider, T, Bordas, M, SCHIFFLERS, C, Arseni, L, Gaupel, A-C, Kilpert, F, Krötschel, M, Arnold, S J, Sellner, L, Colomer, D, Stilgenbauer, S, Dietrich, S, Lichter, P, Izcue, A & Seiffert, M 2021, ' EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia ', Leukemia, vol. 35, no. 8, pp. 2311-2324 . https://doi.org/10.1038/s41375-021-01136-1
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Roessner, P M, Llaó Cid, L, Lupar, E, Roider, T, Bordas, M, SCHIFFLERS, C, Arseni, L, Gaupel, A-C, Kilpert, F, Krötschel, M, Arnold, S J, Sellner, L, Colomer, D, Stilgenbauer, S, Dietrich, S, Lichter, P, Izcue, A & Seiffert, M 2021, ' EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia ', Leukemia, vol. 35, no. 8, pp. 2311-2324 . https://doi.org/10.1038/s41375-021-01136-1
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Published by Springer Nature, London
Published by Springer Nature, London
Autor:
Min Fang, Frederick R. Appelbaum, Brent L. Wood, H. Joachim Deeg, Roland B. Walter, Gary Schoch, Evandro D. Bezerra, Linde M. Morsink, Brenda M. Sandmaier, Megan Othus, Marco Mielcarek
Publikováno v:
Leukemia
Leukemia, 34(6), 1701-1705. Nature Publishing Group
Leukemia, 34(6), 1701-1705. Nature Publishing Group
Autor:
Silke Heidenreich, Uwe Platzbecker, Marie Robin, Dietger Niederwieser, Dietrich W. Beelen, Arnon Nagler, Arnold Ganser, Johan Maertens, Arne Brecht, Nicolaus Kröger, Per Ljungman, Johannes Schetelig, Gérard Socié, Matthias Stelljes, Linda Koster, Antonin Vitek, Michel van Gelder, Liesbeth C. de Wreede, Jürgen Finke, Ghulam J. Mufti, Liisa Volin, Guido Kobbe, Ibrahim Yakoub-Agha, Thomas Luft
Publikováno v:
Leukemia, 33(3), 686-695. Nature Publishing Group
Leukemia
Leukemia, 33(3), 686-695
Leukemia
Leukemia, 33(3), 686-695
The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT
Autor:
Elizabeth A. Raetz, Amrana Quereshi, M. Zwaan, Nirali N. Shah, Keith J. August, Mignon L. Loh, Susan R. Rheingold, Luciano Dalla-Pozza, Richard Sposto, Jean-Pierre Bourquin, Maryalice Stetler-Stevenson, Deepa Bhojwani, Constance M. Yuan, Sarah Alexander, Paul G. Schlegel, Aurelie Cabannes, Jennifer L. McNeer, Maureen M. O'Brien, Vilmarie Rodriguez, Claudia Rossig
Publikováno v:
Leukemia, 33(4), 884-892. Nature Publishing Group
Leukemia, vol 33, iss 4
Leukemia
Leukemia, vol 33, iss 4
Leukemia
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/ref
Autor:
E. De Bruyne, Lucienne Michaux, Cecilia Mancini, Iwona Wlodarska, Karin Vanderkerken, H Lemmens, Emanuela Garelli, Pieter Sonneveld, Isabel J.F. Hofman, Ellen Geerdens, Michel Delforge, M. van Duin, Anna Aspesi, K. De Keersmaecker, Laura Fancello, George Mulligan, Peter Vandenberghe
Publikováno v:
Leukemia, 31(8), 1706-1714. Nature Publishing Group
Leukemia
Leukemia
Chromosomal region 1p22 is deleted in ≥20% of multiple myeloma (MM) patients, suggesting the presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we delimit a 58 kb minimal deleted region (MDR) on 1p22.1 encompassi
Autor:
J Zhou, J Wu, B Li, D Liu, J Yu, X Yan, S Zheng, J Wang, L Zhang, F He, Q Li, A Chen, Y Zhang, X Zhao, Y Guan, J Yan, J Ni, M A Nobrega, B Löwenberg, R Delwel, P J M Valk, A Kumar, L Xie, D G Tenen, G Huang, Q-f Wang
Publikováno v:
Leukemia, 28(7), 1436-1448. Nature Publishing Group
Mixed lineage leukemia (MLL) fusion proteins directly activate the expression of key downstream genes such as MEIS1, HOXA9 to drive an aggressive form of human leukemia. However, it is still poorly understood what additional transcriptional regulator
Autor:
Bart Barlogie, J.J. Lahuerta, Brian G.M. Durie, Fiona M. Ross, Roman Hájek, Orhan Sezer, Norma C. Gutiérrez, Nicoletta Testoni, Pieter Sonneveld, Jeff Haessler, John Crowley, Michele Cavo, Philippe Moreau, R Fonseca, S.V. Rajkumar, Hervé Avet-Loiseau, M. Attal, Je-Hwan Lee, H. Goldschmidt, Gareth J. Morgan
Publikováno v:
Leukemia, 27(3), 711-717. Nature Publishing Group
The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic